2 4 1 partitioning. 41 42-44 Most lysosomotropic agents belong to the class of cationic amphiphilic drugs 2 4 2 (CADs) containing both a hydrophobic and a hydrophilic domain. CADs have increased probability 2 4 3 to cause drug-induced phospolipidosis (PLD), 45 a lysosomal storage disorder characterized by the 2 4 4 accumulation of phospholipids within the lysosome by unclear molecular mechanisms, leading to 2 4 5 cellular stress. [46] [47] [48] [49] [50] Indeed among the lysosomotropic drugs involved in the most transcriptionally 2 4 6 0 similar drug-pairs (Table 1) , there were also three known PLD inducing drugs (astemizole, 2 4 7 suloctidil and trifluoperazine).
4 8
We hypothesised that "lysosomotropic" stress induced by these compounds could explain 2 4 9 their similarity in transcriptional responses. We therefore selected 187 CAD compounds present in 2 5 0 CMAP according to their physico-chemical properties (LogP >3; pKa >7.4) 43 . Within these CAD 2 5 1 compounds, we searched the literature for lysosomotropic drugs known to induce PLD, 45 which, 2 5 2 according to our hypothesis, should elicit a strong transcriptional response. We thus identified a 2 5 3 total of 35 compounds (PLD/CAD) (Supplementary Table 3 ).
5 4
We verified that PLD/CAD compounds tend to induce a stronger transcriptional response 2 5 5 (i.e. a lower TV) ( Supplementary Fig. 12 ) and they tend to be transcriptionally similar among them 2 5 6 (but not structurally) despite having different mode of action and therapeutic applications 2 5 7
( Supplementary Fig. 13 ).
5 8
We next asked which genes were transcriptionally modulated by the majority of PLD/CAD 2 5 9 compounds. We performed Drug Set Enrichment Analysis (DSEA), 51 a computational approach we 2 6 0 recently developed to identify gene-sets that are transcriptionally modulated by most drugs in a 2 6 1 given set. The most significant gene-set shared by the 35 PLD/CAD compounds, out of about 2 6 2 5,000 gene-sets within the Gene Ontology (GO) database, was the GO-Cell Component term 2 6 3 "lysosome" consisting mainly of genes coding for lysosomal enzymes and ion channels 2 6 4 (p=5.03x10 -8 - Supplementary Table 4) , thus in agreement with the "lysosomotropic" effect of 2 6 5 these drugs.
6 6
Recently, the transcription factor E-box (TFEB) has been found to be a major player in the 2 6 7 transcriptional control of lysosomal genes in response to a variety of cellular and environmental 2 6 8 stresses. 52 In normal nutrient conditions TFEB is phosphorylated by the mTORC1 complex on the 2 6 9 lysosomal surface. This phosphorylation favours TFEB binding to 14-3-3 proteins and its retention 2 7 0 in the cytoplasm. [53] [54] [55] Upon stress signal, such as nutrient deprivation, mTOR is inhibited, the 2 7 1 calcium-dependent phosphatase Calcineurin is activated, and TFEB is de-phosphorylated shuttling 2 7 2 to the nucleus where it transcriptionally controls lysosomal biogenesis, exocytosis and 2 7 3 1 autophagy. [53] [54] [55] [56] [57] [58] [59] Moreover, TFEB was shown to translocate to the nucleus upon amiodarone 2 7 4 treatment, a well known lysosomotropic agent. 60 We thus decided to investigate whether TFEB 2 7 5 activation was responsible for the characteristic transcriptional response induced by PLD/CAD 2 7 6 compounds. 2 7 7 2 7 8
The transcriptional response of PLD-inducing compounds is mediated by TFEB 2 7 9
We performed a panel of High Content Screening assays including the TFEB nuclear 2 8 0 translocation assay (TFEB-NT) 59 at 3h and 24h following drug administration at different 2 8 1 concentrations (0.1µM, 1µM and 10µM) for 34 out of 35 PLD drugs (1 drug was not available to us 2 8 2 at the time). Additional HCS assays at 24h included LAMP-1 immunostaining and Lysotracker dye 2 8 3 to quantify lysosomal compartment (Methods), GM130 and PDI immunostaining to detect 2 8 4 morphological changes in the Golgi and ER (Endoplasmic Reticulum) compartments, both of which 2 8 5 have been recently suggested to be involved in PLD aetiology (Methods). We also performed the 2 8 6
LipidTox assay at 48h to check for the accumulation of phospholipids to confirm PLD at least in 2 8 7 vitro (Methods).
8 8
Quantification of the HCS assays for the 34 PLD drugs are reported in Supplementary 2 8 9 Figure 13 and Supplementary Table 5. Nuclear translocation of TFEB at 3h was observed for 18 2 9 0 out of 34 drugs (53%) increasing to 29 drugs at 24h (85%). Out of these 29 drugs, 27 induced an 2 9 1 increase in lysosome size and number as evidenced by LAMP1 and Lysotracker staining, and all 2 9 2 29 drugs induced accumulation of phospholipids according to the Lipidtox assay (100%). Only 5 2 9 3 drugs did not induce TFEB translocation at 24h, and just 1 out of these 5 drugs was positive in the 2 9 4
Lysotracker assay, while 4 of them were positive in the Lipidtox assay. None of the drugs tested 2 9 5
were positive for the Golgi marker and only 6 were positive for the ER marker, albeit marginally.
9 6
Overall, HCS confirmed a concentration dependent nuclear translocation of TFEB for 29 out 2 9 7 of 34 drugs (85% at 24h) with a concomitant perturbation of the lysosomal compartment for 28 out 2 9 8 of 34 drugs (82%) occurring mostly at the highest dosage tested (10 µM). Furthermore, HCS 2 9 9 revealed an accumulation of lipid in vitro at 48h following treatment with the 34 drugs (100%) at the 3 0 0 highest dosage tested (10 µM), as previously reported in the literature. with similar functions) is a consequence of lysosomal stress upon compound treatment or if it is 3 0 5 directly related to the induction of the PLD phenotype. Thus, we set up a HCS Lipidtox assay using 3 0 6 TFEB wt versus TFEB/TFE3 KO in HeLa cell type, administering high dosage of chloroquine (50 3 0 7 µM) known to induce lipids accumulation in cells at 48h. Supplementary Fig. 15a, b show no 3 0 8 major differences in terms of spot intensity in the Lipidtox assay, thus confirming that TFEB 3 0 9 activation is a consequence of lysosomal stress and not an inducer of PLD. We combined the transcriptional responses elicited by the 35 PLD/CAD compounds into a 3 1 8 consensus transcriptional response ("PLD" signature) and computed its transcriptional distance 3 1 9 from all the other 1274 (i.e. 1309-35) CMAP compounds (Methods). We reasoned that drugs 3 2 0 inducing a transcriptional profile similar to the PLD signature should have a higher probability of 3 2 1 inducing lipid accumulation than the other drugs. Surprisingly, 258 compounds out of 1274 (20%) 3 2 2 cMAP compounds were found to be similar to the PLD signature (Supplementary Table 6 ). About 3 2 3 a third of these drugs are CADs (77 out of 258 (30%)). 3 2 4
Figure 5 reports a breakdown by ATC classes of drugs for which an ATC code was 3 2 5 available and that were found to induce a transcriptional response similar to the PLD signature. 3 2 6
Some drug classes (ATC classes N05, N06 and R06 including antihistamines and antipsychotics) 3 2 7 are enriched for known PLDs 45, 47 . Other classes cause global cellular stress responses not 3 2 8 mediated by their physico-chemical properties, but rather because of their direct molecular targets, 3 2 9 such as anticancer compounds that block cell-cycle (e.g. ATC class L01 composed of CDK2 and 3 3 0 Topoisomerase I, II inhibitors). Antihelmintics (ATC P02) and antifungals (ATC D01), despite being 3 3 1 neither CADs nor PLDs, were also found among the PLD node's neighbours. Several recent 3 3 2 reports in the literature have found antihelmintics to induce an anti-proliferative effect in cancer cell 3 3 3 lines by indirectly inhibiting the mTOR pathway thus inducing TFEB activity, which may explain 3 3 4 their PLD-like transcriptional response. 55, [60] [61] [62] [63] Calcium channel blockers were also found to induce 3 3 5 a transcriptional response similar to PLDs, which may be expected since calcium signalling has 3 3 6 been involved in autophagy regulation and lysosomal function. 59 Interestingly, some cardenolides 3 3 7
(ATC C01 and C07) were also found to contain the PLD signature, despite not being CADs 3 3 8 (median distance equal to 0.71).
64, 65

9
To experimentally validate the usefulness of the PLD transcriptional signature in identifying 3 4 0 novel PLD drugs, we selected the top quartile of the 258 drugs (i.e. 25% of 258=64 drugs) with the 3 4 1 shortest transcriptional distance to the PLD node and performed HCS for lipid accumulation 3 4 2 following drug treatment at three different concentrations (Lipidtox assay) (Supplementary Table  3 4 3 7). Twenty-two out of the top 64 small molecules were present in our HCS small-molecule library. 3 4 4
Overall 11 out of 22 (50%) compounds were positive to the Lipidtox assay (Supplementary Table  3 We also uncovered a transcriptional signature common to a subset of transcriptionally 4 0 2 similar but structurally distinct drugs profiled in CMAP that is not related to their mode of action, but 4 0 3 rather to cellular toxicity caused by lysosomal stress and lipid accumulation. Based on the results here presented, we suggest guidelines to prevent inconsistencies and 4 2 2 erroneous conclusion when using transcriptional responses of small molecules for drug discovery 4 2 3 and drug repositioning: (i) the transcriptional response elicited by a drug can be uninformative.
2 4
Hence these responses must be detected and then excluded from further analyses. We 4 2 5 demonstrated that this can be achieved by assessing the Transcriptional Variability (TV) of the 4 2 6 drug-induced transcriptional response across multiple replicates; (ii) drug treatment can cause 4 2 7 cellular stress unrelated to the drug MoA and thus affect the drug-induced transcriptional response 4 2 8 by partially masking transcriptional changes directly related to the drug molecular targets. We 4 2 9 generated a PLD transcriptional signature which can be used to detect these compounds. This as described before (Supplementary Fig. 1 ). The total number of chemical structure used for 4 5 0 further analysis was thus equal to 5452.
5 1
The ChemAxon Standardizer tool (v. 14.9) was run to convert SMILES string annotations 4 5 2 into 2D multi-SDF structural files. 74 The "remove fragments" and "neutralize" options were used to 4 5 3 fix all the molecular structures, to remove counter-ions and other various kinds of molecular 4 5 4 fragments, which may be present in branded drug formulation but not useful in this work (e.g. pharmacophores derived from the MIFs were used to align molecules with specific biological 4 8 6 activity. 30, 77, 78 The evaluation of MIF volume superimpositions between the two structures is 4 8 7 reported as a similarity score ranging from 0 to 1 for each of the three probes. A global score 4 8 8 (GLOB-Sum) is then obtained as the sum of the three scores of the individual probes. Higher 4 8 9 GLOB-S values correspond to more similar structures. For this study, we transformed the GLOB-4 9 0 Sum similarity score matrix (S) of dimension 5452x5452 into a distance matrix defined as D=1-S/3. 4 9 1
Since the distance matrix is symmetric (i.e. the distance between A and B is the same as 4 9 2 the distance between B and A), the total number of drug-pairs to consider is 14,859,426 (5452 x 4 9 3 5451 /2). 4 9 4
Construction of the drug network 4 9 5
We ranked drug-pairs according to their structural distance in ascending order and 4 9 6 considered as significant only those drug-pairs in the top 5% of the ranked list, as previously 4 9 7 described by Iorio et. al. 4 to reduce the total amount of egdes in the MANTRA network (The 4 9 8 distance threshold is 0.51 when considering the 5452x5452 network or 0.65 when considering only 4 9 9 the CMAP 1309x1309 sub-network). We then represented drugs as nodes connected by edges. 5 0 0
The resulting Structural Drug Network has a giant connected component with 5312 nodes (i.e., 5 0 1 drugs) out of 5,452 and 35,527 edges, corresponding to 5% of a fully connected network with the 5 0 2 same number of nodes (14,859,426 edges) (Supplementary Fig. 4) . In order to visualise and 5 0 3 extract useful information from the SDN, we identified communities via the Affinity Propagation 5 0 4
Clustering algorithm, as implemented in the R package apcluster (v. 1.3.5).
32, 79 A community is 5 0 5 defined as a group of nodes densely interconnected with each other and with fewer connections to 5 0 6 nodes outside the group. 80 Each community was coded with a numerical identifier, a colour, and 5 0 7 one of its nodes was identified as the "exemplar" of the community, i.e., the drug whose effect best 5 0 8
represents the effects of the other drugs in the community. LysoTracker Red DND-99), Golgi (GM130) and ER (PDI) were acquired using an automated 5 7 3 confocal microscopy (Opera High Content System, Perkin-Elmer). The fluorescent intensity and 5 7 4 area of the different stainings were analyzed by using dedicated scripts developed in the Columbus 5 7 5
Image Data Management and Analysis Software (Perkin-Elmer). 
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